This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Thanks everybody for attending. Isaac Ro from Goldman Sachs; I am the Life Science analyst here and certainly happy to have the management team from Quidel here with us today. So you know as with all the other presentations I want to make sure that I will keep it as interactive as possible and so by all means please don't be shy to ask a question. Raise your hand if you like anytime in the conversation and we will be sure of calling you and for those of you on the webcast as well, please feel free to ping me with an email if you want. I am happy to read back your question anonymously of course and we will go from there.
So with that as a backdrop, Doug if you maybe first get everyone situated. There has been a lot of going on at Quidel in evolving the company over the last couple of years and Doug to make sure we get proper context, so if you could spend a few minutes and can give us a background on the company and your key financial goals for this year that will be great.
Okay sure, terrific. The company has been around for a while. The history of the company actually is predominantly rapid point of care diagnostic test as early as 1985 we developed and commercialized a pregnancy test fold truly thereafter by a group based prep test. And then in the 1999 we co-developed with Glaxo the first flu assay which has had several iterations to that product. And so for the most part up until about 2008, we for the most part a company that participated very nicely in the rapid point of care diagnostics space. I came on Board in 2009. The Board gave me the mandate of diversifying our product portfolio, developing a broader based diagnostic business, a business that's certainly less dependent on flu. We don't mind the seasonality of flu. We dislike it when we don't see any flu at all.